
Standard Member
Cagliptide (CAS Cagrilintide,CAS No.: 1415456-99-3) is a new type of polypeptide raw material drug, with the molecular formula of C, H, N, O, S, and a molecular weight of about 4270 Da. As an amylin analog, it acts by regulating appetite and blood glucose metabolism and is primarily used in the combination treatment of obesity and type 2 diabetes (e. g., in combination with selmegraglutide). The polypeptide achieves a weight loss effect by delaying gastric emptying and enhancing satiety, and is clinically shown to significantly reduce body weight and have good safety. Cold chain preservation (2-8 ℃) is required, which is suitable for the development of injection preparations. At present, it is developed by Novo Nordisk and other enterprises, and some of them are in the clinical trial stage.